Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pee test vs. scope: which do bladder cancer patients prefer?

NCT ID NCT06126796

Diagnosis Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study asked 107 people with a history of non-muscle invasive bladder cancer whether they preferred a non-invasive urine test (CxBladder Monitor) or the standard cystoscopy (a thin tube inserted into the bladder) for routine cancer surveillance. Participants tried both methods and reported their preference and satisfaction. The goal is to see if the easier urine test could be a more comfortable option for regular check-ups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CxBladder Monitor (urine-based molecular test)
What this could lead to
If successful, this could show that patients prefer a simple urine test over an invasive scope for routine bladder cancer check-ups, potentially making surveillance less uncomfortable.
What could go wrong
This is a small, completed study focused on patient preference, not on whether the urine test catches cancer as well as cystoscopy. The test might miss some recurrences, so it may not replace cystoscopy entirely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

107 people

The number who actually took part.

Started

Nov 2023

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Male or female adult patients who are undergoing cystoscopic surveillance for NMIBC after at least 9 months of recurrence-free survival.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female with a history of histologically confirmed nonmuscle invasive bladder cancer (NMIBC) who have at least 6 months of disease-free survival from last recurrence. * Able to provide urine for testing and comply with study protocol. * Have an email address and be willing to complete surveys online. Exclusion Criteria: * History of non-urothelial bladder cancer (primary squamous, adenocarcinoma, and small cell carcinoma) * Patients with predominant (\>50%) variant histology * Patients with a history of upper tract and/or urethral cancer * Women who are pregnant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-muscle invasive bladder cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-muscle invasive bladder cancer

Contacts and locations

Locations

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, 85259, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.